The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Glasdegib plus low-dose cytarabine for elderly AML patients who have failed HMAs
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, talks on the findings of a study investigating the use of glasdegib in combination with low-dose cytarabine for the treatment of elderly patients with acute myeloid leukemia (AML) who have previously failed treatment with hypomethylating agents (HMAs). Response were evaluated in 13 patients. Dr Zucenka reports that the overall response rate was 46%, with four patients achieving a complete response. The median duration of response was two months. The median overall survival at a median follow-up of 13.2 months was 6.5 months. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
